The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: A potential drug target and biomarker

Breast Cancer Research

Volumn 15, Issue 2, 2013, Pages

  Salmans, Michael L ^a   Zhao, Fang ^b   Andersen, Bogi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; CYCLIN D1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN REGULATED ANTERIOR GRADIENT 2 PROTEIN; MEMBRANE PROTEIN; MYC PROTEIN; PROTEIN DISULFIDE ISOMERASE; SURVIVIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AGR2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; PROTEIN; TUMOR MARKER;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; EXTRACELLULAR MATRIX; HUMAN; LOSS OF FUNCTION MUTATION; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MASTECTOMY; METASTASIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876731685     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3408     Document Type: Review

References (72)

1. Kuang WW, Thompson DA, Hoch RV, Weigel RJ. Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res 1998, 26:1116-1123. 10.1093/nar/26.4.1116, 147366, 9461476.
2. Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998, 251:111-116. 10.1006/bbrc.1998.9440, 9790916.
3. Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, Daviet L, Legrain P, Parekh R, Harris AL, Terrett JA. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 2003, 88:579-585. 10.1038/sj.bjc.6600740, 2377166, 12592373.
4. Maresh E L, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer 2010, 10:680. 10.1186/1471-2407-10-680, 3009682, 21144054.
5. Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee EJ, Choi YL, Song SY, Bae DS, Kim BG, Lee JH. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 2011, 43:91-100. 10.3858/emm.2011.43.2.011, 3047197, 21200134.
6. Pizzi M, Fassan M, Balistreri M, Galligioni A, Rea F, Rugge M. Anterior gradient 2 overexpression in lung adenocarcinoma. Appl Immunohistochem Mol Morphol 2012, 20:31-36. 10.1097/PAI.0b013e3182233f9f, 21768879.
7. Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008, 68:7811-7818. 10.1158/0008-5472.CAN-08-1320, 18829536.
8. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008, 68:492-497. 10.1158/0008-5472.CAN-07-2930, 18199544.
9. Fritzsch e FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 2006, 12:1728-1734. 10.1158/1078-0432.CCR-05-2057, 16551856.
10. Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, Rha SY. Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Oncol Rep 2011, 25:717-727.
11. Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, Langdon S, Murray E, Larionov A, Petrakova K, Muller P, Dixon MJ, Hupp TR, Vojtesek B. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 2010, 29:4838-4847. 10.1038/onc.2010.228, 20531310.
12. Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res 2010, 12:R32. 10.1186/bcr2586, 2917027, 20525379.
13. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005, 65:3796-3805. 10.1158/0008-5472.CAN-04-3823, 15867376.
14. Norris AM, Gore A, Balboni A, Young A, Longnecker DS, Korc M. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene 2012, doi: 10.1038, 10.1038/onc.2012.394, 22945649.
15. Higa A, Mulot A, Delom F, Bouchecareilh M, Nguyên DT, Boismenu D, Wise MJ, Chevet E. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem 2011, 286:44855-44868. 10.1074/jbc.M111.275529, 3248018, 22025610.
16. Benham AM. The protein disulfide isomerase family: key players in health and disease. Antioxid Redox Signal 2012, 16:781-789. 10.1089/ars.2011.4439, 22142258.
17. Aberger F, Weidinger G, Grunz H, Richter K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev 1998, 72:115-130. 10.1016/S0925-4773(98)00021-5, 9533957.
18. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003, 278:6482-6489. 10.1074/jbc.M210184200, 12477722.
19. Petek E, Windpassinger C, Egger H, Kroisel PM, Wagner K. Localization of the human anterior gradient-2 gene (AGR2) to chromosome band 7p21.3 by radiation hybrid mapping and fluorescencein situ hybridisation. Cytogenet Cell Genet 2000, 89:141-142. 10.1159/000015594, 10965104.
20. Verma S, Salmans ML, Geyfman M, Wang H, Yu Z, Lu Z, Zhao F, Lipkin SM, Andersen B. The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development. Dev Biol 2012, 369:249-260. 10.1016/j.ydbio.2012.06.030, 22819674.
21. Gray TA, MacLaine NJ, Michie CO, Bouchalova P, Murray E, Howie J, Hrstka R, Maslon MM, Nenutil R, Vojtesek B, Langdon S, Hayward L, Gourley C, Hupp TR. Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. J Immunol Methods 2012, 378:20-32. 10.1016/j.jim.2012.01.013, 22361111.
22. Bu H, S chweiger MR, Manke T, Wunderlich A, Timmermann B, Kerick M, Pasqualini L, Shehu E, Fuchsberger C, Cato AC, Klocker H. Anterior gradient 2 and 3 - two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells. FEBS J 2013, 280:1249-1266. 10.1111/febs.12118, 23294566.
23. Fullwoo d MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, Karuturi RK, Herve T, Bourque G, Stunnenberg HG, Ruan X, Cacheux-Rataboul V, Sung WK, Liu ET, Wei CL, Cheung E, Ruan Y. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64. 10.1038/nature08497, 2774924, 19890323.
24. Persson S, Rosenquist M, Knoblach B, Khosravi-Far R, Sommarin M, Michalak M. Diversity of the protein disulfide isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol 2005, 36:734-740. 10.1016/j.ympev.2005.04.002, 15935701.
25. Innes H E, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 2006, 94:1057-1065. 10.1038/sj.bjc.6603065, 2361240, 16598187.
26. Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley J, West CR, Rudland PS. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 2009, 175:1848-1857. 10.2353/ajpath.2009.090246, 2774050, 19834055.
27. Zweitzi g DR, Smirnov DA, Connelly MC, Terstappen LW, O'Hara SM, Moran E. Physiological stress induces the metastasis marker AGR2 in breast cancer cells. Mol Cell Biochem 2007, 306:255-260. 10.1007/s11010-007-9562-y, 17694278.
28. Perou C M, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
29. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
30. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
31. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2011, 31:1196-1206. 3307061, 21785460.
32. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006, 13:617-628. 10.1677/erc.1.01165, 16728587.
33. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali H R, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393. 3272464, 22217937.
34. Welboren W-J, Driel M, Janssen-Megens EM, Heeringen S, Sweep FC, Span PN, Stunnenberg HG. ChIP-Seq of ER|[alpha]| and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009, 28:1418-1428. 10.1038/emboj.2009.88, 2688537, 19339991.
35. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005, 43:249-259. 10.1002/gcc.20188, 15834940.
36. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007, 9:R37. 10.1186/bcr1732, 1929101, 17555561.
37. Hengel SM, Murray E, Langdon S, Hayward L, O'Donoghue J, Panchaud A, Hupp T, Goodlett DR. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J Proteome Res 2011, 10:4567-4578. 10.1021/pr2004117, 3242698, 21936522.
38. Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, Mahoney CJ, Shioda K, Isselbacher KJ, Ramaswamy S, Shioda T. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 2009, 106:14536-14541. 10.1073/pnas.0907560106, 2732824, 19706540.
39. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar T C, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339. 10.1038/sj.onc.1206937, 14576841.
40. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367:435-444. 10.1056/NEJMoa1201622, 22853014.
41. Tveito S, Andersen K, Karesen R, Fodstad T. Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles. Breast Cancer Res 2011, 13:R75. 10.1186/bcr2922, 3236339, 21816090.
42. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pie nta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65:4993-4997. 10.1158/0008-5472.CAN-04-4330, 15958538.
43. da Costa A, Lenze D, Hummel M, Kohn B, Gruber AD, Klopfleis ch R. Identification of six potential markers for the detection of circulating canine mammary tumour cells in the peripheral blood identified by microarray analysis. J Comp Pathol 2012, 146:143-151. 10.1016/j.jcpa.2011.06.004, 21783201.
44. Marín-Aguilera M, Mengual L, Ribal MJ, Ars E, Ríos J, Gázquez C, Villavicencio H, Alcaraz A. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology 2012, 79:240.e249-215. 10.1016/j.urology.2011.09.006, 22055693.
45. Valladares-Ayerbes M, Díaz-Prado S, Reboredo M, Medina V, Igle sias-Díaz P, Lorenzo-Patiño MJ, Campelo RG, Haz M, Santamarina I, Antón-Aparicio LM. Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect Prev 2008, 32:236-250. 10.1016/j.cdp.2008.08.002, 18801625.
46. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837. 10.1016/j.cell.2009.02.024, 2894612, 19269363.
47. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006, 8:1053-1063. 10.1038/ncb1471, 16964246.
48. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772. 10.1038/nrc1716, 16175177.
49. Simpson NE, Lambert WM, Watkins R, Giashuddin S, Huang SJ, Oxelmar k E, Arju R, Hochman T, Goldberg JD, Schneider RJ, Reiz LF, Soares FA, Logan SK, Garabedian MJ. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res 2010, 70:8446-8456. 10.1158/0008-5472.CAN-10-1590, 3007122, 20847343.
50. Sevier CS, Kaiser CA. Formation and transfer of disulphide bonds in living cells. Nat Rev Mol Cell Biol 2002, 3:836-847. 10.1038/nrm954, 12415301.
51. Zhao F, Edwards R, Dizon D, Afrasiabi K, Mastroianni JR, Geyfman M, Ouellette AJ, Andersen B, Lipkin SM. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. Dev Biol 2010, 338:270-279. 10.1016/j.ydbio.2009.12.008, 2937056, 20025862.
52. Kang K, Park B, Oh C, Cho K, Ahn K. A role for protein disulfide isomerase in the early folding and assembly of MHC class I molecules. Antioxid Redox Signal 2009, 11:2553-2561. 10.1089/ars.2009.2465, 19388826.
53. Cho K, Cho S, Lee SO, Oh C, Kang K, Ryoo J, Lee S, Kang S, Ahn K. Redoxregulated peptide transfer from the transporter associated with antigen processing to major histocompatibility complex class I molecules by protein disulfide isomerase. Antioxid Redox Signal 2011, 15:621-633. 10.1089/ars.2010.3756, 21299467.
54. Lee HJ, Hong CY, Kim MH, Lee YK, Nguyen-Pham TN, Park BC, Yang DH, Chung IJ, Kim HJ, Lee JJ. In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. Exp Mol Med 2012, 44:60-67. 10.3858/emm.2012.44.1.006, 3277899, 22089087.
55. Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, Brentnall TA, Bronner MP, Feakins RM, Timms JF, Brennan C, Lemoine NR, Crnogorac-Jurcevic T. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 2011, 71:7091-7102. 10.1158/0008-5472.CAN-11-1367, 3541941, 21948970.
56. Park SW, Zhen G, Verhaeghe C, Nakagami Y, Nguyenvu LT, Barczak AJ, Killeen N, Erle DJ. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA 2009, 106:6950-6955. 10.1073/pnas.0808722106, 2678445, 19359471.
57. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009, 9:874-885. 10.1038/nrc2761, 2951677, 19935676.
58. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 2011, 1815:224-240. 3230300, 21277939.
59. Wang J, Jarrett J, Huang CC, Satcher RL, Levenson AS. Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. Clin Exp Metastasis 2007, 24:411-422. 10.1007/s10585-007-9078-6, 17593529.
60. Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006, 21:295-305. 10.1016/j.molcel.2005.11.030, 16427018.
61. Schroeder BW, Verhaeghe C, Park SW, Nguyenvu LT, Huang X, Zhen G, Erle DJ. AGR2 is induced in asthma and promotes allergen-induced mucin overproduction. Am J Respir Cell Mol Biol 2012, 47:178-185. 10.1165/rcmb.2011-0421OC, 22403803.
62. Zhang Y, Ali TZ, Zhou H, D'Souza DR, Lu Y, Jaffe J, Liu Z, Passaniti A, Hamburger AW. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res 2010, 70:240-248. 10.1158/0008-5472.CAN-09-2904, 20048076.
63. Maslon MM, Hrstka R, Vojtesek B, Hupp TR. A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin. J Mol Biol 2010, 404:418-438. 10.1016/j.jmb.2010.09.035, 20888340.
64. Kim JH, Choi HJ, Kim B, Kim MH, Lee JM, Kim IS, Lee MH, Choi SJ, Kim KI, Kim SI, Chung CH, Baek SH. Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat Cell Biol 2006, 8:631-639. 10.1038/ncb1415, 16699503.
65. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008, 132:945-957. 10.1016/j.cell.2008.01.019, 2291539, 18358808.
66. Rashid S, Pilecka I, Torun A, Olchowik M, Bielinska B, Miaczynska M. Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription. J Biol Chem 2009, 284:18115-18128. 10.1074/jbc.M109.007237, 2709337, 19433865.
67. Qi D, Jin H, Lilja T, Mannervik M. Drosophila Reptin and other TIP 60 complex components promote generation of silent chromatin. Genetics 2006, 174:241-251. 10.1534/genetics.106.059980, 1569795, 16816423.
68. Bellosta P, Hulf T, Balla Diop S, Usseglio F, Pradel J, Aragnol D, Gallant P. Myc interacts genetically with Tip48/Reptin and Tip49/Pontin to control growth and proliferation during Drosophila development. Proc Natl Acad Sci USA 2005, 102:11799-11804. 10.1073/pnas.0408945102, 1187951, 16087886.
69. Dong A, Gupta A, Pai RK, Tun M, Lowe AW. The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation. J Biol Chem 2011, 286:18301-18310. 10.1074/jbc.M110.215707, 3093902, 21454516.
70. Ambolet-Camoit A, Bui LC, Pierre S, Chevallier A, Marchand A, Coumoul X, Garlatti M, Andreau K, Barouki R, Aggerbeck M. 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2. Toxicol Sci 2010, 115:501-512. 10.1093/toxsci/kfq082, 20299546.
71. Pohler E, Craig AL, Cotton J, Lawrie L, Dillon JF, Ross P, Kernohan N, Hupp TR. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 2004, 3:534-547. 10.1074/mcp.M300089-MCP200, 14967811.
72. Imamura T, Hikita A, Inoue Y. The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis. Breast Cancer 2012, 19:118-124. 10.1007/s12282-011-0321-2, 22139728.